Breakthrough Innovation for Animal Health, Upcoming Conference Presentations, and New Treatment Options for Patients - Analyst Notes on Merck, Actavis, Celgene, Bristol-Myers Squibb and GSK

NEW YORK, May 29, 2014 /PRNewswire/ --

Today, Analysts Review released its analysts' notes regarding Merck & Co., Inc. (NYSE: MRK), Actavis plc (NYSE: ACT), Celgene Corporation (NASDAQ: CELG), Bristol-Myers Squibb Co. (NYSE: BMY) and GlaxoSmithKline plc (NYSE: GSK). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.analystsreview.com/3057-100free.

--
Merck & Co., Inc. Analyst Notes
On May 20, 2014, Merck Animal Health, the global animal health business unit of Merck & Co., Inc. (Merck) announced that the U.S. Food and Drug Administration has approved BRAVECTO™ (fluralaner) - chewable tablets for dogs available in 112.5 mg, 250 mg, 500 mg, 1000 mg, 1400 mg. It is the first and only treatment to quickly and effectively kill fleas and multiple tick species for 12 days in a single dose, and is effective for 8 weeks against Amblyomma americanum ticks, stated the Company. KJ Varma, Senior Vice President, Research and Development, Merck Animal Health said; "The approval of BRAVECTO is truly a reflection of our 70-year history of innovation, research and commitment to helping shape the future of animal health, as well as our dedication to bringing novel products to market that meet the evolving needs of pet owners, customers and the industry." The full analyst notes on Merck are available to download free of charge at:

http://www.analystsreview.com/MRK.pdf/Register

--
Actavis plc Analyst Notes
On May 21, 2014, Actavis plc (Actavis) announced that its Chairman and CEO, Paul Bisaro, will present at the Goldman Sachs 35th Annual Global Healthcare Conference 2014 on June 11, 2014, at 11:20 a.m. PDT, at the Terranea Resort, Rancho Palos Verdes, California. Mr Bisaro will provide an overview and update of the Company's business, and a live webcast of the presentation will be made available at the Company's website. In addition, Actavis informed that an archived version can be accessed an hour after the presentation via the same website, which will be available for 90 days thereafter. The full analyst notes on Actavis are available to download free of charge at:

http://www.analystsreview.com/ACT.pdf/Register

--
Celgene Corporation Analyst Notes
On May 20, 2014, Celgene Corporation (Celgene) announced that its management will present at three upcoming investor conferences namely; Jefferies 2014 Global Healthcare Conference on June 4, 2014, at 10:00 a.m. ET, in New York; William Blair Growth Stock Conference on June 11, 2014, at 2:20 p.m. ET, in Chicago and; Goldman Sachs 35th Annual Global Healthcare Conference on June 11, 2014, at 1:00 p.m. ET, in Rancho Palos Verdes, California. Celgene informed that its management will provide an overview of the Company at the three upcoming investor conferences, and the live webcasts of each of the conferences will be made available at its website. The full analyst notes on Celgene are available to download free of charge at:

http://www.analystsreview.com/CELG.pdf/Register

--
Bristol-Myers Squibb Co. Analyst Notes
On May 21, 2014, Bristol-Myers Squibb Co. (Bristol-Myers Squibb) announced that 20 abstracts for Orencia® (abatacept) and clazakizumab, have been accepted for presentation at the 2014 annual meeting of the European League Against Rheumatism (EULAR), which will be held from June 11, 2014 to June 14, 2014 in Paris, France. According to the Company, the extensive data to be presented reflects the Company's commitment to develop innovative treatments for rheumatoid arthritis (RA) patients and other immune-mediated diseases including its pioneering T-cell co-stimulation modulator, Orencia and clazakizumab, an investigational selective IL-6 cytokine inhibitor. The full analyst notes on Bristol-Myers Squibb are available to download free of charge at:

http://www.analystsreview.com/BMY.pdf/Register

--
GlaxoSmithKline plc Analyst Notes
On May 23, 2014, GlaxoSmithKline plc (ADR) (GSK) and Genmab A/S announced that they have received positive opinion from the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA), recommending a variation to the terms of the marketing authorization for Arzerra™ (ofatumumab) for a new indication in combination with chlorambucil or bendamustine as a first-line treatment for patients with chronic lymphocytic leukemia (CLL) who are not eligible for fludarabine-based therapy. Dr Rafael Amado, Head of Oncology R&D at GSK said, "This CHMP opinion for Arzerra in the first-line setting brings GSK one step closer to offering a new treatment option for patients with previously untreated CLL in Europe." The full analyst notes on GSK are available to download free of charge at:

http://www.analystsreview.com/GSK.pdf/Register

--
About Analysts Review
We do things differently. Our goal is to provide the best content to our exclusive membership. We are constantly hiring researchers, writers, editors and analysts to add to our team and become better than yesterday. If being a part of a fast growing community with an edge in today's market sounds interesting to you, then sign-up today and experience the full benefits of membership.


===============
EDITOR'S NOTES:
===============

1. This is not company news. We are an independent source and our views do not reflect the companies mentioned.

2. Information in this release is produced on a best efforts basis by Rohit Tuli, a CFA charterholder. The content is then further fact checked and reviewed by an outsourced research provider. However, we are only human and are prone to make mistakes. If you notice any errors or omissions, please notify us below.

3. This information is submitted as a net-positive to companies mentioned, to increase awareness for mentioned companies to our subscriber base and the investing public.

4. If you wish to have your company covered in more detail by our team, or wish to learn more about our services, please contact us at pubco [at] www.analystsreview.com.

5. For any urgent concerns or inquiries, please contact us at compliance [at] www.analystsreview.com.

6. Are you a public company? Would you like to see similar coverage on your company? Send us a full investors' package to research [at] www.analystsreview.com for consideration.

COMPLIANCE PROCEDURE
Content is researched, written and reviewed on a best-effort basis. This document, article or report is prepared and authored by Analysts Review, represented by Rohit Tuli, CFA. An outsourced research services provider has only reviewed the information provided by Analysts Review in this article or report according to the procedures outlined by Analysts Review. Analysts Review is not entitled to veto or interfere in the application of such procedures by the outsourced provider to the articles, documents or reports, as the case may be.

NOT FINANCIAL ADVICE
Analysts Review makes no warranty, expressed or implied, as to the accuracy or completeness or fitness for a purpose (investment or otherwise), of the information provided in this document. This information is not to be construed as personal financial advice. Readers are encouraged to consult their personal financial advisor before making any decisions to buy, sell or hold any securities mentioned herein.

NO WARRANTY OR LIABILITY ASSUMED
Analysts Review is not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted by Analysts Review whatsoever for any direct, indirect or consequential loss arising from the use of this document. Analysts Review expressly disclaims any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Analysts Review does not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.

SOURCE Analysts Review

WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM?

440k+
Newsrooms &
Influencers

9k+
Digital Media
Outlets

270k+
Journalists
Opted In

GET STARTED